Skip to main content

ABI, Hitachi Renew Pact to Develop, Sell CE-Based DNA Sequencers

NEW YORK, Jan. 5 (GenomeWeb News) - Applied Biosystems and Hitachi High-Technologies Corporation have renewed and amended a 1997 alliance to co-develop and commercialize capillary electrophoresis-based DNA-analysis technologies, ABI said today.

Terms of the agreement call for the companies to continue to be exclusive collaborators in the development and commercialization of CE-based instruments for research, applied market, and diagnostic applications. The current product line includes ABI's 3130 and 3730 DNA analyzers.

 

Katsuji Yamashita, senior vice president of Hitachi High-Technologies, said  his company "will also continue to develop new technologies to serve future demands of the genetic analysis market."

 

Financial terms of the agreement were not disclosed.

 

It was not immediately clear how the collaboration was amended. Calls to ABI and Hitachi High-Technologies' USaffiliate, which are both based in California, were not immediately returned.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.